# CareDx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/caredx

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.xdx.com
- Total disclosed funding: $101M
- Latest round: Series G (Aug 5, 2009)
- Investors on record: 11

## About

CareDx, Inc. is a biotechnology company specializing in transplant diagnostics, providing innovative noninvasive testing solutions to improve patient outcomes in organ transplantation.Founded in 1998 in Brisbane, US, CareDx, Inc. offers advanced solutions for the transplant sector, particularly for kidney, heart, and lung transplants. The company has pivoted over the years to focus on noninvasive testing, such as AlloSure and AlloMap. Jay Graham is the founder, and the current executives include Anders Karlsson, D Wightman, Peter Maag, Reginald Seeto, and Terence Dphil. CareDx has raised a total of USD 22.16 mn, with the latest funding round being a PIPE amounting to USD 22.16 mn.CareDx specializes in providing noninvasive surveillance tests for transplant patients, such as AlloSure and AlloMap, which utilize advanced cell-free DNA (cfDNA) technology. These products enable healthcare professionals to monitor transplant health effectively. Additionally, CareDx offers comprehensive software and services to enhance operational processes within transplant centers, ensuring better patient management. They serve over 150 transplant centers in North America and are working toward expanding their international market presence.In the most recent fiscal year 2024, CareDx reported a revenue of USD 333.79 mn and an EBITDA of USD 60.52 mn. Their revenue model is based on direct sales of testing products and software services to healthcare providers and transplant centers, which reflects their advanced technological contributions to patient care.CareDx plans to launch new products designed to enhance monitoring in the transplant sector, with specific release dates to be announced. The company is targeting expansion into international markets to increase its reach and accessibility, with concrete plans to penetrate these regions by 2025. The recent PIPE funding round of USD 22.16 mn will be utilized to support these initiatives, ensuring that CareDx can further enhance its product offerings and expand its market presence.

## Funding rounds

- Series G, Aug 5, 2009, $14M — Burrill & Company, Kleiner Perkins, Sprout Group, Intel Capital, DAG Ventures, Integral Capital Partners, TPG Biotech, Bristol-Myers Squibb Company
- Series F, May 1, 2007, $26M — Burrill & Company, Kleiner Perkins, Sprout Group, Integral Capital Partners, TPG Biotech, Duff Ackerman & Goodrich Private Equity
- Series E, Jan 5, 2006, $27M — Burrill & Company, Kleiner Perkins, Sprout Group, Intel Capital, DAG Ventures, Integral Capital Partners, JP Morgan Asset Management, TPG Biotech, DBL Partners
- Series D, Dec 1, 2004, $20M — Burrill & Company, Kleiner Perkins, Sprout Group, Integral Capital Partners, JP Morgan Asset Management, TPG Biotech
- Series C, Jun 30, 2004, $9.4M — Kleiner Perkins
- Series C, Jan 31, 2003, $5M — Kleiner Perkins

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series C, Series D, Series E, Series F, Series G
- Burrill & Company (https://capitalatlas.ai/funds/burrill-company) — Series D, Series E, Series F, Series G
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series D, Series E, Series F, Series G
- Integral Capital Partners (https://capitalatlas.ai/funds/integral-capital-partners) — Series D, Series E, Series F, Series G
- JP Morgan Asset Management (https://capitalatlas.ai/funds/jp-morgan-asset-management) — Series D, Series E
- TPG Biotech (https://capitalatlas.ai/funds/tpg-biotech) — Series D, Series E, Series F, Series G
- Intel Capital (https://capitalatlas.ai/funds/intel-capital) — Series E, Series G
- DAG Ventures (https://capitalatlas.ai/funds/dag-ventures) — Series E, Series G
- DBL Partners (https://capitalatlas.ai/funds/dbl-partners) — Series E
- Duff Ackerman & Goodrich Private Equity (https://capitalatlas.ai/funds/duff-ackerman-goodrich-private-equity) — Series F
- Bristol-Myers Squibb Company — Series G